Kiora Pharmaceuticals (KPRX) Enterprise Value (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Enterprise Value came in at -$13.9 million in Q1 2026, up 42.45% YoY from -$9.7 million in Q1 2025, and up 18.92% on a QoQ basis from -$17.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Enterprise Value (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Enterprise Value data on file, last reported at -$13.9 million in Q1 2026.
- Quarterly Enterprise Value rose 42.45% year-over-year to -$13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.9 million (up 42.45% YoY) and the FY2025 annual result came in at -$17.1 million, up 36.23% from the prior year.
- Enterprise Value climbed to -$13.9 million in Q1 2026, from -$17.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.5 million in Q4 2023 to a low of -$31.3 million in Q1 2024.
- A 5-year average of -$14.6 million and a median of -$13.9 million in 2026 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 59.11% — and 2024, when it sank 989.74%.
- Tracing KPRX's Enterprise Value over 5 years: stood at -$6.0 million in 2022, then surged by 59.11% to -$2.5 million in 2023, then slumped by 989.74% to -$26.8 million in 2024, then soared by 36.23% to -$17.1 million in 2025, then advanced by 18.92% to -$13.9 million in 2026.
- The last three Enterprise Value figures came in at -$13.9 million (Q1 2026), -$17.1 million (Q4 2025), and -$19.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | -16.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.90 Mn |
| Mar 31, 2026 | -13.86 Mn |
| Dec 31, 2025 | -17.09 Mn |
| Sep 30, 2025 | -19.37 Mn |
| Jun 30, 2025 | -20.64 Mn |
| Mar 31, 2025 | -24.08 Mn |
| Dec 31, 2024 | -26.80 Mn |
| Sep 30, 2024 | -29.04 Mn |
| Jun 30, 2024 | -27.82 Mn |
| Mar 31, 2024 | -31.28 Mn |
| Dec 31, 2023 | -2.46 Mn |
| Sep 30, 2023 | -5.40 Mn |
| Jun 30, 2023 | -7.96 Mn |
| Mar 31, 2023 | -3.43 Mn |
| Dec 31, 2022 | -6.01 Mn |
| Sep 30, 2022 | -4.85 Mn |
| Jun 30, 2022 | -2.48 Mn |
| Mar 31, 2022 | -5.11 Mn |
| Dec 31, 2021 | -7.90 Mn |
| Sep 30, 2021 | -11.15 Mn |